Kiniksa Pharmaceuticals International, plc Net Income (Loss) Attributable to Parent in USD from Q2 2017 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Kiniksa Pharmaceuticals International, plc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2017 to Q3 2025.
  • Kiniksa Pharmaceuticals International, plc Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2025 was $18.4M.
  • Kiniksa Pharmaceuticals International, plc Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2025 was $35.9M.
  • Kiniksa Pharmaceuticals International, plc annual Net Income (Loss) Attributable to Parent for 2024 was -$43.2M, a 407% decline from 2023.
  • Kiniksa Pharmaceuticals International, plc annual Net Income (Loss) Attributable to Parent for 2023 was $14.1M, a 92.3% decline from 2022.
  • Kiniksa Pharmaceuticals International, plc annual Net Income (Loss) Attributable to Parent for 2022 was $183M.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)

Kiniksa Pharmaceuticals International, plc Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $35.9M $18.4M +$31.1M Jul 1, 2025 Sep 30, 2025 10-Q 2025-10-28
Q2 2025 $4.79M $17.8M +$21.7M Apr 1, 2025 Jun 30, 2025 10-Q 2025-10-28
Q1 2025 -$17M $8.54M +$26.2M Jan 1, 2025 Mar 31, 2025 10-Q 2025-10-28
Q4 2024 -$43.2M -$8.89M -$34.1M -135% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-25
Q3 2024 -$9.07M -$12.7M +$1.16M +8.39% Jul 1, 2024 Sep 30, 2024 10-Q 2025-10-28
Q2 2024 -$10.2M -$3.91M -$18.9M -126% Apr 1, 2024 Jun 30, 2024 10-Q 2025-10-28
Q1 2024 $8.65M -$17.7M -$5.43M -44.3% Jan 1, 2024 Mar 31, 2024 10-Q 2025-10-28
Q4 2023 $14.1M $25.2M +$20.8M +466% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-25
Q3 2023 -$6.69M -$13.9M -$238M -106% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-29
Q2 2023 $231M $15M +$35M Apr 1, 2023 Jun 30, 2023 10-Q 2024-10-29
Q1 2023 $196M -$12.3M +$12.9M +51.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-10-29
Q4 2022 $183M $4.46M +$40.8M Oct 1, 2022 Dec 31, 2022 10-K 2025-02-25
Q3 2022 $143M $224M +$255M Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 -$112M -$20M +$21.6M +51.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-02
Q1 2022 -$134M -$25.2M +$24.3M +49.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-02
Q4 2021 -$158M -$36.3M +$17.3M +32.3% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 -$175M -$30.5M +$13.3M +30.3% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$189M -$41.6M -$4.09M -10.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-03
Q1 2021 -$184M -$49.5M -$23.1M -87.3% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-03
Q4 2020 -$161M -$53.7M -$21.9M -68.7% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-02
Q3 2020 -$140M -$43.8M -$16.8M -62% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$123M -$37.5M -$278K -0.75% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-04
Q1 2020 -$122M -$26.4M +$39.4M +59.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-04
Q4 2019 -$162M -$31.8M +$10.8M +25.3% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-24
Q3 2019 -$173M -$27.1M -$2.65M -10.9% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$170M -$37.2M -$16.9M -83.6% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-05
Q1 2019 -$153M -$65.8M -$49.8M -312% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-05
Q4 2018 -$103M -$42.6M Oct 1, 2018 Dec 31, 2018 10-K 2021-02-25
Q3 2018 -$24.4M -$8.38M -52.3% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-05
Q2 2018 -$20.3M -$9.06M -80.8% Apr 1, 2018 Jun 30, 2018 10-Q 2019-11-05
Q1 2018 -$16M Jan 1, 2018 Mar 31, 2018 10-Q 2019-11-05
Q3 2017 -$16M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-06
Q2 2017 -$11.2M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-06

Kiniksa Pharmaceuticals International, plc Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$43.2M -$57.3M -407% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-25
2023 $14.1M -$169M -92.3% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-25
2022 $183M +$341M Jan 1, 2022 Dec 31, 2022 10-K 2025-02-25
2021 -$158M +$3.46M +2.14% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-28
2020 -$161M +$486K +0.3% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-02
2019 -$162M -$58.6M -56.8% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-24
2018 -$103M -$38.4M -59.1% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-25
2017 -$64.9M Jan 1, 2017 Dec 31, 2017 10-K 2019-03-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.